Effect of Anagliptin and Sitagliptin on low-density lipoprotein cholesterol in patients with type 2 diabetes and cardiovascular risk factors: Randomized controlled trial
Not Applicable
- Registration Number
- JPRN-UMIN000017064
- Lead Sponsor
- Institute for Clinical Effectiveness
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with type 1 diabetes 2) Patients with triglyceride equal to or greater than 400 mg/dL in the previous fasting measuments 3) Patients with pregnancy, possible pregnancy, or on breast-feeding 4) Patients with severe infections, perioperative status, or severe trauma 5) Patients with elevated creatinine (>=2.4 mg/dl for men; >=2.0 mg/dl for women) 6) Patients who were received glucagon-like peptide-1receptor agonists 7) Patients whom physician in charge considered inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in low-density lipoprotein cholesterol Change in glycated hemoglobin
- Secondary Outcome Measures
Name Time Method